Andrew McRiner, PhD

VP, Head of Drug Discovery

Dr. McRiner joined Auron Therapeutics in December 2020 as VP, Head of Drug Discovery. Most recently he was Director and Head of Medicinal Chemistry at X-Chem Pharmaceuticals, building drug discovery capabilities on top of a highly efficient DNA-Encoded Library (DEL) Screening platform. Dr. McRiner was a founding member of a 25-member team developing a portfolio of 8 small molecule and 8 Protac therapeutic programs derived from DEL screening. In total, Dr. McRiner has almost 20 years of experience leading drug discovery programs at pharmaceutical companies such as Novartis, Schering-Plough and Merck, and contributing to the maturation of smaller biotechs such as Helicon Therapeutics (renamed as DART Neuroscience) and Forum Pharmaceuticals (originally Envivo Pharmaceuticals). He has experience leading projects in multiple therapeutic areas, most prominently oncology and CNS. He is co-inventor on over 25 patent applications and has contributed to the nomination of 12 compounds for clinical development.

Dr. McRiner completed postdoctoral studies with Professor Gary Posner at Johns Hopkins University, exploring the antimalarial properties of artemisinin-related trioxanes. He received his PhD in Organic Chemistry under the tutelage of Professor Timothy J. Donohoe at The University of Manchester (UK), developing the first Birch reductions on aromatic heterocycles as a means to access saturated and partially saturated heterocycles of therapeutic interest.

When not working, Andy loves spending time outdoors with his wife and two daughters hiking, skiing and snowboarding in Maine. He looks forward to resuming international travel and visiting new places post-COVID.